A weakening British pound presents a two-front challenge for Novo Nordisk A/S, the Danish insulin producer. It has hurt revenues in the U.K., while also pressuring prices in some European countries, said finance chief Jesper Brandgaard. Exporters have been exploiting the weaker pound following last year’s decision by U.K. voters to exit from the European Union by re-exporting Novo’s products to other continental European countries,...

Source: Wall Street Journal May 03, 2017 18:00 UTC